Total Payments
$542,470
2022 Payments
$90.00
Companies
11
Transactions
94
Payment Breakdown by Category
Research$520,272 (95.9%)
Consulting$13,435 (2.5%)
Other$4,388 (0.8%)
Travel$3,185 (0.6%)
Food & Beverage$1,108 (0.2%)
Education$82.20 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $520,272 | 48 | 95.9% |
| Consulting Fee | $13,435 | 7 | 2.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,388 | 1 | 0.8% |
| Travel and Lodging | $3,185 | 13 | 0.6% |
| Food and Beverage | $1,108 | 24 | 0.2% |
| Education | $82.20 | 1 | 0.0% |
Payments by Type
Research
$520,272
48 transactions
General
$22,199
46 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CIPLA USA INC. | $220,512 | 15 | $0 (2020) |
| Glenmark Pharmaceuticals Inc. | $214,222 | 17 | $0 (2018) |
| Circassia Pharmaceuticals Inc | $72,863 | 8 | $0 (2017) |
| Teva Pharmaceuticals USA, Inc. | $14,416 | 18 | $0 (2021) |
| AstraZeneca AB | $10,745 | 5 | $0 (2020) |
| Mylan Inc. | $5,596 | 14 | $0 (2019) |
| GlaxoSmithKline, LLC. | $2,690 | 2 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $1,092 | 10 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $218.95 | 3 | $0 (2019) |
| GENZYME CORPORATION | $101.79 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $90.00 | 1 | GlaxoSmithKline, LLC. ($90.00) |
| 2021 | $2,385 | 2 | Teva Pharmaceuticals USA, Inc. ($2,385) |
| 2020 | $23,014 | 12 | AstraZeneca AB ($10,745) |
| 2019 | $227,049 | 33 | Cipla USA Inc. ($220,488) |
| 2018 | $41,285 | 15 | Glenmark Pharmaceuticals Inc. ($40,193) |
| 2017 | $248,647 | 31 | Glenmark Pharmaceuticals Inc. ($174,029) |
All Payment Transactions
94 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/16/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $90.00 | General |
| Category: IMMUNOLOGY | ||||||
| 03/02/2021 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $1,035.00 | Research |
| Study: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | ||||||
| 02/01/2021 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $1,350.00 | Research |
| Study: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | ||||||
| 12/01/2020 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $1,350.00 | Research |
| Study: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | ||||||
| 11/04/2020 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $1,410.00 | Research |
| Study: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | ||||||
| 10/06/2020 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $1,380.00 | Research |
| Study: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | ||||||
| 09/03/2020 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $1,440.00 | Research |
| Study: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | ||||||
| 08/10/2020 | AstraZeneca AB | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 08/10/2020 | AstraZeneca AB | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 07/31/2020 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $4,065.00 | Research |
| Study: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | ||||||
| 06/22/2020 | AstraZeneca AB | — | Consulting Fee | Cash or cash equivalent | $3,144.99 | General |
| 04/18/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: RESPIRATORY | ||||||
| 04/16/2020 | AstraZeneca AB | — | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| 04/16/2020 | AstraZeneca AB | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 01/06/2020 | CIPLA USA INC. | FLUTICASONE PROPIONATE + SALMETEROL (Drug) | — | Cash or cash equivalent | $24.19 | Research |
| Study: U-FS-MU-AS3120 • Category: PULMONARY DISORDERS | ||||||
| 12/16/2019 | Cipla USA Inc. | FLUTICASONE PROPIONATE AND SALMETEROL (Drug) | — | Cash or cash equivalent | $217.73 | Research |
| Study: U-FS-MU-AS3120 • Category: PULMONARY DISORDERS | ||||||
| 12/09/2019 | Cipla USA Inc. | FLUTICASONE PROPIONATE AND SALMETEROL (Drug) | — | Cash or cash equivalent | $19,176.00 | Research |
| Study: U-FS-MU-AS3120 • Category: PULMONARY DISORDERS | ||||||
| 12/05/2019 | Cipla USA Inc. | FLUTICASONE PROPIONATE AND SALMETEROL (Drug) | — | Cash or cash equivalent | $31,202.07 | Research |
| Study: U-FS-MU-AS3120 • Category: PULMONARY DISORDERS | ||||||
| 12/05/2019 | Cipla USA Inc. | FLUTICASONE PROPIONATE AND SALMETEROL (Drug) | — | Cash or cash equivalent | $1,458.86 | Research |
| Study: U-FS-MU-AS3120 • Category: PULMONARY DISORDERS | ||||||
| 12/03/2019 | Cipla USA Inc. | FLUTICASONE PROPIONATE AND SALMETEROL (Drug) | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: U-FS-MU-AS3120 • Category: PULMONARY DISORDERS | ||||||
| 12/03/2019 | Cipla USA Inc. | FLUTICASONE PROPIONATE AND SALMETEROL (Drug) | — | Cash or cash equivalent | $10.04 | Research |
| Study: U-FS-MU-AS3120 • Category: PULMONARY DISORDERS | ||||||
| 11/27/2019 | Cipla USA Inc. | FLUTICASONE PROPIONATE AND SALMETEROL (Drug) | — | Cash or cash equivalent | $8,500.00 | Research |
| Study: U-FS-MU-AS3120 • Category: PULMONARY DISORDERS | ||||||
| 11/27/2019 | Cipla USA Inc. | FLUTICASONE PROPIONATE AND SALMETEROL (Drug) | — | Cash or cash equivalent | $7,800.00 | Research |
| Study: U-FS-MU-AS3120 • Category: PULMONARY DISORDERS | ||||||
| 11/27/2019 | Cipla USA Inc. | FLUTICASONE PROPIONATE AND SALMETEROL (Drug) | — | Cash or cash equivalent | $5,300.00 | Research |
| Study: U-FS-MU-AS3120 • Category: PULMONARY DISORDERS | ||||||
| 11/21/2019 | Cipla USA Inc. | FLUTICASONE PROPIONATE AND SALMETEROL (Drug) | — | Cash or cash equivalent | $42,811.59 | Research |
| Study: U-FS-MU-AS3120 • Category: PULMONARY DISORDERS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| U-FS-MU-AS3120 | Cipla USA Inc. | $220,488 | 14 |
| GSP 301-303 | Glenmark Pharmaceuticals Inc. | $160,825 | 6 |
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $72,863 | 8 |
| GSP301-304 | Glenmark Pharmaceuticals Inc. | $13,204 | 6 |
| A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $12,674 | 8 |
| U-FS-MU-AS3120 | CIPLA USA INC. | $24.19 | 1 |
About Dr. Gordon Raphael, M.D
Dr. Gordon Raphael, M.D is a Allergy & Immunology healthcare provider based in Bethesda, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1619003167.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gordon Raphael, M.D has received a total of $542,470 in payments from pharmaceutical and medical device companies, with $90.00 received in 2022. These payments were reported across 94 transactions from 11 companies. The most common payment nature is "" ($520,272).
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Bethesda, MD
- Active Since 02/26/2007
- Last Updated 07/08/2007
- Taxonomy Code 207K00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1619003167
Products in Payments
- FLUTICASONE PROPIONATE AND SALMETEROL (Drug) $220,488
- Wixela Inhub (Drug) $5,596
- NUCALA (Biological) $2,690
- MK-7264 (Drug) $1,092
- Fluticasone Propionate and Salmeterol (Drug) $644.26
- FASENRA (Drug) $214.08
- DUPIXENT (Drug) $101.79
- QVAR (Drug) $69.98
- FLUTICASONE PROPIONATE + SALMETEROL (Drug) $24.19
- CINQAIR (Drug) $18.01
- Oralair (Drug) $12.90
- SYMBICORT (Drug) $4.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Allergy & Immunology Doctors in Bethesda
Dean Metcalfe, M.d, M.D
Allergy & Immunology — Payments: $4,297
Allergy & Immunology $4,297
Dr. Jack Ragheb, M.d., Ph.d, M.D., PH.D
Allergy & Immunology — Payments: $1,874
Allergy & Immunology $1,874
Dr. Nayoung Kim, M.d, M.D
Allergy & Immunology — Payments: $1,066
Allergy & Immunology $1,066
Jenna Bergerson, M.d, M.D
Allergy & Immunology — Payments: $924.77
Allergy & Immunology $924.77
Dr. Jay Montgomery, M.d, M.D
Allergy & Immunology — Payments: $604.06
Allergy & Immunology $604.06
Dr. Cecilia Mikita, Md, Mph, MD, MPH
Allergy & Immunology — Payments: $347.84
Allergy & Immunology $347.84